Menu

Find clinical trials for Asthma in Ann Arbor, MI

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Nasal Polyps
Rhinosinusitis
Allergic Rhinitis
Rhinitis
Sinusitis
Respiration Disorders
A woman searches for clinical trials

Asthma trials near Ann Arbor, MI, USA:

administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..Study det...

Enrolling
Severe Asthma
Combination Product: Budesonide/formoterol
Combination Product: Mannitol

Phase 3

AstraZeneca
AstraZeneca

Windsor, Ontario, Canada and 83 other locations

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma...

Enrolling
Asthma
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Toledo, Ohio, United States and 125 other locations

is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma...

Enrolling
Asthma
Asthma; Eosinophilic
Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

Phase 3

Areteia Therapeutics

Warren, Michigan, United States and 45 other locations

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will e...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

Phase 2

Upstream Bio

Farmington Hills, Michigan, United States of America and 122 other locations

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma...

Active, not recruiting
Asthma Attack
Asthma; Eosinophilic
Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

Phase 3

Areteia Therapeutics

Dearborn, Michigan, United States and 196 other locations

to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma...

Enrolling
Asthma
Other: Placebo
Drug: Dupilumab

Phase 4

Boston Children's Hospital
Boston Children's Hospital

Detroit, Michigan, United States and 6 other locations

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...

Enrolling
Asthma
Biological: Tezepelumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Ann Arbor, Michigan, United States and 115 other locations

Locations recently updated

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations....

Enrolling
Asthma
Drug: Placebo
Drug: Rocatinlimab

Phase 2

Amgen
Amgen

Ypsilanti, Michigan, United States and 125 other locations

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated w...

Begins enrollment in 2 months
Eosinophilic Asthma
Combination Product: Placebo for Benralizumab
Combination Product: benralizumab

Phase 3

AstraZeneca
AstraZeneca

Ann Arbor, Michigan, United States and 22 other locations

To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied pop...

Active, not recruiting
Asthma
Drug: Tezepelumab

Phase 4

AstraZeneca
AstraZeneca

Ann Arbor, Michigan, United States and 34 other locations